Center-Authored Papers

Filters: Author is Duerr, Ann  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert PB, Loufty M, Mehrotra D, Duerr A.  2011.  An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).. The Journal of infectious diseases. 203(6):765-72. Abstract
Hayes PJ, Cox JH, Coleman AR, Fernandez N, Bergin PJ, Kopycinski JT, Nitayaphan S, Pitisuttihum P, de Souza M, Duerr A et al..  2016.  Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.. AIDS (London, England). 30(11):1703-1712. Abstract
Duerr A, Altice FL, Harries AD, Sohn AH.  2012.  Antiretroviral treatment in resource-limited settings 2012.. AIDS research and treatment. 2012:346708.
Duerr A, Gallo MF, Warner L, Jamieson DJ, Kulczycki A, Macaluso M.  2011.  Assessing male condom failure and incorrect use.. Sexually transmitted diseases. 38(7):580-6. Abstract
C
Saganic L, Carr J, Solorio R, Courogen M, Jaenicke T, Duerr A.  2012.  Comparing Measures of Late HIV Diagnosis in Washington State.. AIDS research and treatment. 2012:182672. Abstract
D
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
E
Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, Rompalo AM, Cu-Uvin S, Duerr A.  2009.  The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology.. Obstetrics and gynecology. 113(1):26-31. Abstract
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC et al..  2015.  Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.. PloS one. 10(9):e0136626. Abstract
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, del Rio C et al..  2008.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.. Lancet. 372(9653):1881-93. Abstract
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L et al..  2012.  Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266. Abstract
Duerr A, Huang Y.  In Press.  Extended follow-up of participants in a cell-mediated immunity HIV vaccine trial (Step study): Vaccine effect on HIV acquisition in male wanes over time. Journal of Infectious Diseases.
F
Kingkeow D, McNicholl JM, Maneekarn N, Wongtrakul J, Taechareonkul S, Suriyanon V, Nelson KE, Duerr A, Makonkawkeyoon S.  2011.  Frequencies of IL10 SNP genotypes by multiplex PCR-SSP and their association with viral load and CD4 counts in HIV-1-infected Thais.. Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand. 29(1):94-101. Abstract
G
Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A et al..  2011.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.. Nature medicine. 17(3):366-71. Abstract
H
Theiler RN, Farr SL, Karon JM, Paramsothy P, Viscidi R, Duerr A, Cu-Uvin S, Sobel J, Shah K, Klein RS et al..  2010.  High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding.. Obstetrics and gynecology. 115(6):1150-8. Abstract
Duerr A.  2012.  HIV treatment as protection: next steps.. Current opinion in HIV and AIDS. 7(2):97-8.
Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP et al..  2015.  HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.. Nature medicine. Abstract
Frahm N, Decamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP et al..  2012.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67. Abstract
I
Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, McElrath MJ, Gilbert PB.  2014.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.. PloS one. 9(11):e108631. Abstract
Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D et al..  2010.  Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.. PloS one. 5(8):e11995. Abstract
Jaspan HB, Cunningham CK, Tucker TJP, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker L-G, Wilson CM, Duerr A et al..  2008.  Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.. Journal of acquired immune deficiency syndromes (1999). 47(1):86-92. Abstract
K
Wandell GM, Molina Y, Sánchez H, Greer AC, Ríos J, Bain C, Segura P, Lama JR, Sánchez J, Duerr A.  2017.  Knowledge and preferences concerning acute HIV testing programs among both Peruvian men who have sex with men and transgender women.. International journal of STD & AIDS. :956462416685674. Abstract
M
van der Horst C, Chasela C, Ahmed Y, Hoffman I, Hosseinipour M, Knight R, Fiscus S, Hudgens M, Kazembe P, Bentley M et al..  2009.  Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi.. Contemporary clinical trials. 30(1):24-33. Abstract
O
Gray G, Buchbinder S, Duerr A.  2010.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61. Abstract
P
Maclachlan E, Mayer KH, Barnabas R, Sanchez J, Koblin B, Duerr A.  2009.  The potential role of biomarkers in HIV preventive vaccine trials.. Journal of acquired immune deficiency syndromes (1999). 51(5):536-45. Abstract
R
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Huang Y, Gilbert P et al..  2013.  Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.